Sodium polystyrene sulfonate

Oral
Hyperkalaemia

Rectal
Hyperkalaemia

Oral admin to neonates; neonates with reduced gut motility; obstructive bowel disease. Hypokalaemia.

Renal failure and conditions requiring a restricted sodium intake e.g. heart failure and severe hypertension. Rectal admin to neonates and children. Monitor for electrolyte disturbances and symptoms of hypokalaemia. Discontinue treatment if clinically significant constipation develops. Irrigate colon after admin of enema to ensure removal of resin. Pregnancy; lactation.

Anorexia, nausea, vomiting, constipation, faecal impaction, diarrhoea; hypokalaemia; hypocalcaemia; sodium retention in patients with impaired renal function.

PO/Rectal: C

Overdosage may lead to signs and symptoms of hypokalaemia e.g. irritability, confusion, delayed thought processes, muscle weakness, hyporeflexia, which may progress to frank paralysis and/or apnea. Cardiac arrhythmias may occur. Appropriate measures include correcting serum electrolytes (potassium, calcium), and removing resin from the GI tract by laxatives or enemas.

Reduces absorption of thyroxine and lithium salts. Enhances adverse effects of cardiac glycosides. Potassium-lowering effect may be reduced when used with other cation-containing antacids.

Description: Sodium polysytrene sulfonate exchanges sodium ions for potassium ions and other cations in the GI tract before the resin is excreted in the faeces.
Onset: 2-24 hr.
Pharmacokinetics:
Excretion: Exchanged resin eliminated in the faeces.

Store at 15-30°C.

Antidotes & Detoxifying Agents